龙琥醒脑颗粒治疗急性脑梗死临床疗效及对GFAP、UCH-L1表达的影响  

Clinical Efficacy of Longhu Xingnao Granules in Treating Acute Cerebral Infarction and Its Effect on GFAP and UCH-L1 Expression

作　　者：龚金兵 王小妹[1] 喻坚柏[1] 张占伟[1] 周辉[1] 李利博 高俊 Gong Jinbing;Wang Xiaomei;Yu Jianbai;Zhang Zhanwei;Zhou Hui;Li Libo;Gao Jun(The First Affiliated Hospital of Hunan University of Chinese Medicine,Hunan,Chongsho 410007,China)

机构地区：[1]湖南中医药大学第一附属医院,湖南长沙410007

出　　处：《中国中医急症》2020年第11期1930-1933,共4页Journal of Emergency in Traditional Chinese Medicine

基　　金：湖南省中医药管理局基金项目(201990)。

摘　　要：目的观察龙琥醒脑颗粒对急性脑梗死的治疗效果及其对血清胶质纤维酸性蛋白(GFAP)、泛素羧基末端水解酶-1(UCH-L1)表达的影响并探讨其作用机制。方法急性脑梗死住院患者60例随机分为两组各30例,对照组给予西医常规治疗,治疗组在对照组的基础上加用龙琥醒脑颗粒。采用ELISA法检测两组治疗前及治疗后第7、14日血清GFAP、UCH-L1表达水平,评估两组患者神经功能缺损程度、总体生活能力状态及临床疗效。结果两组患者美国国立卫生研究院卒中量表(NIHSS)评分及血清GFAP、UCH-L1表达水平均较前下降,且治疗组下降更明显(P<0.05或P<0.01);总体生活能力状态治疗组改善更显著(P<0.05);治疗组临床总有效率为90.00%,高于对照组的76.67%(P<0.05)。结论在西医治疗基础上加用龙琥醒脑颗粒能明显减轻急性脑梗死患者急性期神经功能缺损程度,提高临床疗效,其机制可能与其能下调血清GFAP、UCH-L1表达水平有关。Objective:To observe the clinical efficacy of Longhu Xingnao Granules in treating acute cerebral infarction(ACI)and its effect on serum glial fibrillary acidic protein(GFAP)and ubiquitin c-terminal hydrolase-L1(UCH-L1)expression,and to discuss its mechanism.Methods:A total of 60 hospitalized patients were randomly divided into treatment group and control group,30 cases in each group.The control group was given western routine therapy,while treatment group was given Longhu Xingnao Granules on the basis of control group.Enzyme linked immunosorbent assay(ELISA)was used to detect the serum levels of GFAP and UCH-L1 of the two groups before treatment and 7,14 days after treatment,respectively.The National Institutes of Health Stroke Scale(NIHSS),the capability state of life,and the clinical efficacy were evaluated.Results:After treatment,the NIHSS scores and serum levels of GFAP and UCH-L1 in the treatment group and control group decreased,and the decrease in the treatment group was more significant(P<0.05 or P<0.01).The capability state of life improved significantly in both groups(P<0.01),and the treatment group improved more significantly(P<0.05).The clinical total effective rate in the treatment group was 90.00%,which was significantly higher than 76.67%in the control group,the difference was statistically significant(P<0.05).Conclusion:Longhu Xingnao Granules can reduce the degree of neurologic impairment of ACI patients and improve clinical efficacy;its mechanism may be related to the down-regulation of serum GFAP and UCH-L1 levels.

关 键 词：急性脑梗死 龙琥醒脑颗粒 血清胶质纤维酸性蛋白 泛素羧基末端水解酶-1 神经功能缺损评分 临床疗效 

分 类 号：R743.2[医药卫生—神经病学与精神病学]